YJ1206

Overview

YJ1206 is an orally active selective CDK12 / CDK13 PROTAC degrader. YJ1206 induces DNA damage and genomic instability, activates the AKT pathway, and triggers apoptosis . YJ1206 reduces tumor cell viability, inhibits tumor growth, and attenuates tumor cell dissemination. YJ1206 is applicable to research related to prostate cancer and high-grade serous tubo-ovarian cancer . (Pink: CDK12 and CDK13 ligand ( HY-168658 ); Blue: Cereblon E3 ligase ligand; Black: linker).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Ovarian Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Akt

Product Information

• Catalog No.: HY-168555
• CAS No.: 3053716-98-3
• Molecular Formula: C49H52FN11O5
• Molecular Weight: 894.01
• Purity: 97.26%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1 mg/mL (1.12 mM); Clear solution
• Availability: In-stock

Source

Original product source